We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


Clinical trials exploring immunotherapy in bladder cancer

Monday, August 29, 2016

David M. Nanus, M.D., spoke to OncLive about ongoing clinical trials exploring immunotherapy agents for the treatment of patients with bladder cancer.

Currently, there is a trial randomizing patients to receive chemotherapy, a PD-1 inhibitor, or a PD-1 agent plus a CTLA-4 inhibitor, Nanus explains.

Prior data in melanoma suggest that PD-1 plus CTLA-4 regimens have significant activity; therefore, it is hoped that a similar effect will occur in patients with bladder cancer. Another interesting area in this field is determining if immunotherapy has a greater benefit in the neoadjuvant or adjuvant setting.

Additionally, Nanus questions whether immunotherapy could have a role in patients with superficial bladder cancer. More research is needed to determine what other indications these types of agents could have activity in, he adds.